Comparison

Varlitinib European Partner

Item no. HY-10530-10mg
Manufacturer MedChem Express
CASRN 845272-21-1
Amount 10 mg
Quantity options 100 mg 10 mM/1 mL 10 mg 1 mg 50 mg 5 mg
Category
Type Inhibitors
Specific against other
Purity 99.92
Citations [1]Hsieh C, et al. Varlitinib to demonstrate anti-tumour efficacy in patient-derived hepatocellular carcinoma xenograft models. Journal of Clinical Oncology 34, no. 15_suppl|[2]Miknis G, et al. ARRY-334543, A potent, orally active small molecule inhibitor of EGFR and ErbB-2.Proc Amer Assoc Cancer Res, Volume 46, 2005
Smiles C[C@H]1N=C(NC2=CC3=C(NC4=CC=C(OCC5=NC=CS5)C(Cl)=C4)N=CN=C3C=C2)OC1
ECLASS 10.1 32160490
ECLASS 11.0 32160490
UNSPSC 12000000
Alias ASLAN001,ARRY-334543
Shipping Condition Room temperature
Available
Manufacturer - Type
Reference compound
Manufacturer - Applications
Cancer-Kinase/protease
Manufacturer - Targets
EGFR
Shipping Temperature
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight
466.94
Product Description
Varlitinib (ASLAN001) is a potent, reversible, small molecule pan-EGFR inhibitor with IC50s of 7, 2, 4 nM for HER1, HER2 and HER4, respectively[1].
Manufacturer - Research Area
Cancer
Solubility
DMSO: 33.33 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturer - Pathway
JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Isoform
EGFR/ErbB1/HER1; ErbB2/HER2; ErbB4/HER4
Clinical information
Phase 3

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 10 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close